871 results on '"Heidel, Florian"'
Search Results
2. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients
3. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)
4. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
5. Adressen
6. Chronische myeloproliferative Neoplasien (CMPN)
7. Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia
8. Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
9. Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany
10. Pomalidomide combinations are a safe and effective option after daratumumab failure
11. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
12. Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
13. Antiseptic efficacy of two mouth rinses in the oral cavity to identify a suitable rinsing solution in radiation- or chemotherapy induced mucositis
14. Aggregates of nonmuscular myosin IIA in erythrocytes associate with GATA1- and GFI1B-related thrombocytopenia
15. Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia
16. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
17. Primäre Myelofibrose: Diagnostik, Klinik und Therapieoptionen
18. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
19. Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care
20. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera
21. Therapiestrategien bei myeloproliferativen Neoplasien
22. Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML)
23. Dynamic DNA methylation reveals novel cis-regulatory elements in mouse hematopoiesis
24. Characteristics of hospital admission during checkpoint-inhibition therapy.
25. Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms
26. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML
27. Taz protects hematopoietic stem cells from an aging-dependent decrease in PU.1 activity
28. Breakthrough infections in MPN-COVID vaccinated patients
29. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal
30. Significance of men’s health in long-term survivors of allogeneic stem cell transplantation
31. Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
32. Rhabdomyolysis induced by nelarabine
33. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms
34. PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia
35. SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders
36. Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders
37. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
38. SHP1 regulates a STAT6–ITGB3 axis in FLT3ITD-positive AML cells
39. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
40. Risikoadaptierte Therapie chronischer BCR-ABL1-negativer myeloproliferativer Neoplasien
41. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML
42. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia
43. A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
44. Associations of spleen volume with markers of blood count and lipid profile in a large population-based study
45. P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
46. S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q
47. PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
48. Chronische myeloproliferative Neoplasien (CMPN)
49. Gynäkologische Tumoren
50. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.